摘要
目的探究吡格列酮、西格列汀与二甲双胍联合治疗血糖控制不佳的2型糖尿病肥胖患者的临床效果。方法选取我院2013年6月~2014年6月血糖控制不佳的2型糖尿病肥胖患者100例,根据随机数字表法将其分为研究组、对照组,每组50例,研究组进行吡格列酮、西格列汀与二甲双胍联合疗法,对照组仅进行吡格列酮与二甲双胍疗法,两组均治疗3个月,比较两组患者治疗前后糖化血红蛋白（Hb A1c）、餐后2 h血糖（2 h PG）、空腹血糖（FPG）、体质量指数（BMI）;比较两组患者治疗后的空腹胰岛素（FINS）、空腹C肽（CP0）、餐后2 h胰岛素（2 h/INS）、餐后2 h C肽（CP2）水平;比较两组的不良反应发生率。结果治疗后,两组患者的Hb A1c、2 h PG、FPG均有改善,研究组治疗后的Hb A1c、2 h PG、FPG、BMI显著优于对照组（P〈0.05）;治疗后,研究组FINS、CP0、2 h/INS、CP2水平显著优于对照组（P〈0.05）;两组患者恶心、水肿、头痛等不良反应发生率比较,差异无统计学意义（P〉0.05）。结论对血糖控制不佳的2型糖尿病肥胖患者进行吡格列酮、西格列汀与二甲双胍联合疗法,可显著控制血糖水平,降低机体胰岛素抵抗,控制体重,临床效果确切,值得临床推广。
Objective To explore the clinical effects of pioglitazone,sitagliptin combined with metformin in treating type2 diabetes and obesity patients with poor glycemic control.Methods 100 type 2 diabetes and obesity patients with poor glycemic control from June 2013 to June 2014 of our hospital were selected.Patients were divided into study group and control group according to random number table,and each group was 50 cases.Patients in study group were used pioglitazone,sitagliptin and metformin.Patients in control group were only used pioglitazone and metformin.All patients in two groups were treated for 3 months.The clinical index of glycated glycosylated hemoglobin（Hb A1c）,2 hour postprandial blood glucose（2 h PG）,fasting blood glucose（FPG） and body mass index（BMI） in two groups before and after treatment were compared.After treatment,the level of fasting insulin（FINS）,fasting c-peptide（CP〈0）,postprandial 2 h insulin（2 h/INS）and postprandial 2 h C peptide（CP2） in two groups were compared.The rate of adverse effects in two groups were compared.Results After treatment,the Hb A1 c,2 h PG, FPG and BMI in two groups improved;and the Hb A1 c,2 h PG, FPG and BMI in study group was obvious better than of control group respectively after treatment（P〈0.05）.After treatment,the level of FINS,CP〈0,2 h/INS and CP2 in study group was obvious better than that of control group respectively（P〈0.05）.The rate of adverse effects such as nausea,edema and headache compared with no statistical significance（P〉0.05）.Conclusion Conducting pioglitazone,sitagliptin and metformin combination therapy for type 2 diabetes and obesity patients with poor glycemic control can obviously control blood glucose level,decrease body′s resistance to insulin,control body weight and with definite clinical effects.It is worth to popularize in clinic.
出处
《中国当代医药》
2016年第17期38-40,共3页
China Modern Medicine
基金
广东省佛山市医学类科技攻关项目(201208274)
